诺瓦瓦克斯疫苗审批悬而未决,销售额却逆势猛增

生物制品圈
Yesterday

在新冠疫苗的研发与推广历程中,诺瓦瓦克斯(Novavax)的经历备受关注。近日,该公司在第一季度财报中披露的销售数据引发热议,尽管其新冠疫苗在美国食品药品监督管理局(FDA)的审批仍前途未卜,但销售额却实现了大幅增长。这背后有着怎样的故事?又反映出疫苗市场怎样的现状?审批遇阻,疫苗前景迷雾重重自新冠疫情爆发以来,疫苗成为全球抗击疫情的关键武器。诺瓦瓦克斯研发的新冠疫苗 Nuvaxovid 在全球...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10